NeuroOne Medical Technologies (Nasdaq:NMTC) announced today that it received a patent for drug delivery with neural probe devices.
The United States Patent and Trademark Office (USPTO) issued the patent titled “Agent-Delivering Neural Probe Devices and Related Systems and Methods.” It covers novel electrodes that can operate as a standard neural electrode that delivers a treatment agent to a target area of the brain.
A step into the drug delivery space would mark further progress for NeuroOne, which develops thin-film electrode technologies.
The company already has a patent portfolio that includes both neural and spinal cord electrodes. Their unique structures optimize the functionality and minimized profile of those electrodes.
Eden Prairie, Minnesota-based NeuroOne develops the Evo sEEG electrode line. Evo sEEG offers 30 days of recording, monitoring and stimulation of electrical signals at the subsurface level of the brain. The company also develops the OneRF neural ablation system, for which it hopes to earn FDA clearance this year. It records brain activity and enables the ablation of nervous tissue.
“The company continues to strengthen its existing patent portfolio with this recent notification by the USPTO,” NeuroOne CEO Dave Rosa said. “These allowances are especially important as we advance our efforts to partner with existing biopharma companies to offer the next combination device that can provide both drug delivery and sEEG recording capabilities.”
